Defense World
04 Apr 2026, 08:09 UTC · 30w ago
Impact · against what's priced in
MBX Biosciences shows positive momentum with a clear catalyst timeline for its lead candidate in Q3 2025 and a high-potential obesity pipeline. Immune Therapeutics is essentially a non-operating entity with no viable investment case.
No priced-in read yet
What the story claims
4 claims · scored −1 bearish … +1 bullish
MBX Biosciences has a consensus analyst price target of $51.56, implying a potential upside of 56.28%.
More positive than 92% of claims this week
Immune Therapeutics currently does not have significant operations.
Continue reading
5 related stories
The company has a clear catalyst with topline Phase 2 data for MBX 2109 expected in Q3 2025 and a preclinical obesity candidate targeting once-monthly dosing.
Read from the article alone
No priced-in read yet
The company lacks significant operations, rendering it an unattractive investment compared to active clinical-stage peers.
Read from the article alone
Scored by the NIS engine · methodology.
Search tags
More negative than 91% of claims this week
MBX Biosciences' lead candidate MBX 2109 is in Phase 2 trials for chronic hypoparathyroidism with topline data expected in Q3 2025.
More positive than 76% of claims this week
MBX 4291, a GLP-1/GIP co-agonist for obesity, showed preclinical efficacy similar to tirzepatide with potential for once-monthly dosing.
More positive than 62% of claims this week
Which stocks this story touches
More positive than 87% of ticker scores this week
Analysts report a strong consensus rating, a significant potential price upside, and positive clinical progress across its product pipeline.
More negative than 81% of ticker scores this week
The article states the company does not have significant operations and is less favorable than MBX across most compared factors.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
The Motley Fool
17h ago
+69.4%
Price agrees with the score
$55.87 vs $32.99 close before publication (Apr 2) · not market-adjusted
MBX chart →—
No price for IMUN right now — the quote feed didn't answer.
IMUN chart →
